Mackenzie Financial
GILD icon

Mackenzie Financial’s Gilead Sciences GILD Stock Holding History

Mackenzie Financial’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12,600
Closed -$3.42K – 1756
2025
Q2 		$3.42K Buy
+12,600
New +$1.34M ﹤0.01% 1696

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Mackenzie Financial's GILD Position: Q2 2026 in Review

Mackenzie Financial increased its Gilead Sciences (GILD) stake by 100% in Q2 2026, buying an estimated $134M and bringing the position to 2,033,130 shares worth $257M. The position accounts for 0.26% of the portfolio, ranked #74.

Mackenzie Financial first reported a position in GILD in Q2 2013 and has held it in 53 quarters since. The position peaked at $280M in Q2 2025. 2,283 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Mackenzie Financial held 2,033,130 shares of Gilead Sciences worth $257M as of Q2 2026.
  • Mackenzie Financial bought 1,015,911 Gilead Sciences shares in Q2 2026, an estimated $134M.
  • Gilead Sciences made up 0.26% of Mackenzie Financial's portfolio in Q2 2026, its #74 holding.
  • Mackenzie Financial first reported a position in Gilead Sciences in Q2 2013 and has held it in 53 quarters since.
  • Mackenzie Financial's Gilead Sciences position peaked at $280M in Q2 2025.
  • 2,283 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Mackenzie Financial's 13F filing for Q2 2026, filed 13 Aug 2026.